Abstracts tagged "Gout and uric acid"

Abstract Number: 2897 • 2017 ACR/ARHP Annual Meeting
A Non-Coding Genetic Variant Maximally Associated with Serum Urate Levels Is Functionally Linked to HNF4A-Dependent PDZK1 Expression
Tony R. Merriman¹, Sarada Ketharnathan², James Boocock³, Amanda Phipps-Green², Jisha Antony², Megan Leaask², Justin O'Sullivan⁴ and Julia Horsfield², ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of California Los Angeles, Los Angeles, CA, ⁴University of Auckland, Auckland, New Zealand
A non-coding genetic variant maximally associated with serum urate levels is functionally linked to HNF4A-dependent PDZK1 expressionBackground/Purpose: Genome-wide association studies have revealed several dozen genetic…
Abstract Number: 2898 • 2017 ACR/ARHP Annual Meeting
New Mouse Model of Gout Risk Variant, ABCG2 Q141K, Reveals Unexpectedly Severe Molecular and Functional Defect in ABCG2 Mediated Intestinal Uric Acid Secretion
Kazi M. Hoque and Owen M. Woodward, Physiology, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Gout is a common arthritic disease resulting from deposition of monosodium urate crystals in joints and is a consequence of having elevated circulating uric…
Abstract Number: 1106 • 2017 ACR/ARHP Annual Meeting
Association between ABCG2 rs2231142 and Poor Response to Allopurinol: Replication and Meta-Analysis
Mary Wallace¹, Rebecca Roberts², Payal Nanavati³, Jeffrey N Miner³, Nicola Dalbeth⁴, Ruth Topless⁵, Tony R. Merriman⁶ and Lisa K. Stamp⁷, ¹Surgical Sciences, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Ardea Biosciences, San Diego, CA, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁶Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁷University of Otago, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate-lowering drug. However, some patients treated with allopurinol do not achieve serum urate (SU) treatment target of <6mg/dl,…
Abstract Number: 1110 • 2017 ACR/ARHP Annual Meeting
Clinical Features and Risk of Recurrent Attack in Gout Patients According to Serum Urate Levels during an Acute Gout Attack
Jung Sun Lee¹, Seokchan Hong², Oh Chan Kwon², Byeongzu Ghang², Wook Jang Seo³, Doo-Ho Lim⁴, Yong-Gil Kim², Chang Keun Lee² and Bin Yoo², ¹Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Seoul Veterans Hospital, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: To investigate the clinical features and risk of gout recurrence in patients with normouricemia during an acute attack Methods: This study was conducted in…
Abstract Number: 1114 • 2017 ACR/ARHP Annual Meeting
Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout
Ying-Chou Chen Sr.¹, Shih-Chueh Chen², Chung-Tei Chou³, Carl Brown⁴, Jing-Yi Lee⁴, Wei-Shu Lu⁵ and Chang Youh Tsai⁶, ¹Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan, ²Department of Endocrinology, Cheng Ching General Hospital, Taichung, Taiwan, ³Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Medical Research, TWi Biotechnology, Inc., Taipei, Taiwan, ⁵TWi Biotechnology, Inc., Taipei, Taiwan, ⁶Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit. Diacerein is known as an oral…
Abstract Number: 230 • 2016 ACR/ARHP Annual Meeting
A Survey of Knowledge of Optimal Gout Management in an Academic Primary Care Setting
Stefanie Wade¹ and Micha Abeles², ¹Medicine, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, Consulting Rheumatologist, Midstate Medical Center, Meriden, CT
Background/Purpose: We reviewed previous treatment approaches for gout in patients referred to a university rheumatology practice for gout management. All patients met the 2015 American…
Abstract Number: 233 • 2016 ACR/ARHP Annual Meeting
New Cardiovascular Risk Factors Screening in Patients with Gout
Juan Carlos Ordoñez¹, Mariano Andres¹, Francisca Sivera², Loreto Carmona³, Paloma Vela^4,5, Eliseo Pascual^4,5 and Jose Antonio Bernal⁴, ¹RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ²RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ELDA, Elda, Spain, ³Instituto de Salud Musculo Esqueletica, Madrid, Spain, ⁴RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO ALICANTE, Alicante, Spain, ⁵Medicina, Universidad Miguel Hernandez, Elche, Spain
Background/Purpose: Gout is a disease triggered by the crystallization of uric acid in the joints secondary to persistent hyperuricemia, that leads to chronic inflammation. Patients…
Abstract Number: 1225 • 2016 ACR/ARHP Annual Meeting
Serum Uric Acid Testing Practices over Five Years Among Incident Gout Cases
Dena H. Jaffe¹, Arriel Benis², Natalia M. Flores³, Hagit Gabay², Robert Morlock⁴, Alyssa Klein⁵, Dana Y Teltsch⁶, Jonathan Chapnick⁷, Becca Feldman², Yair Molad⁸, Shmuel M Giveon⁹ and Maya Leventer-Roberts², ¹Health Outcomes Research, Kantar Health, Jerusalem, Israel, ²Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel, ³Kantar Health, Foster City, CA, ⁴4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁵AstraZeneca, Gaithersburg, MD, ⁶Evidera, Lexington, MA, ⁷Kantar Health, Horsham, PA, ⁸Rheumatology, Rabin Medical Center, Beilinson, Petah Tikva, Israel, ⁹Clalit Health Services, Tel Aviv, Israel
Background/Purpose: Gout is a chronic inflammatory disorder associated with elevated levels of serum uric acid (sUA), resulting in urate crystal deposits in soft tissues. Uncontrolled…
Abstract Number: 2274 • 2016 ACR/ARHP Annual Meeting
Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2
Alexis Hofherr¹, Meng Li², Michael Kottgen¹ and Owen M. Woodward², ¹Nephrology, University of Freiburg Medical Center, Freiburg, Germany, ²Physiology, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: ABCG2 is a high capacity urate secretory transporter of the renal proximal tubule. The common Q141K ABCG2 mutation causes gout in humans through an…
Abstract Number: 2275 • 2016 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Gout in New Zealand Polynesian People
Tanya Flynn¹, Ruth Topless¹, Murray Cadzow¹, Amanda Phipps-Green¹, Nick Burns¹, Nicola Dalbeth², Lisa K. Stamp³, Jennie Harre Hindmarsh⁴ and Tony R. Merriman⁵, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: The prevalence of gout in New Zealand Polynesian (Māori and Pacific) populations is approximately twice that of the New Zealand European population, with a…
Abstract Number: 2276 • 2016 ACR/ARHP Annual Meeting
Pleiotropic Effect of ABCG2 in Gout
Tony R. Merriman¹, Amanda Phipps-Green², James Boocock², Philip Riches³, Anne-Kathrin Tausche⁴, Timothy Radstake⁵, Matthijs Janssen⁶, Leo .A.B. Joosten⁷, Tim L Jansen⁸, Alexander So⁹, Jennie Harre Hindmarsh¹⁰, Lisa K. Stamp¹¹, Nicola Dalbeth¹² and Rebekah Wrigley², ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Edinburgh, Edinburgh, United Kingdom, ⁴Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Department of Rheumatology, Rijnstate Hospital Arnhem, Arnhem, Netherlands, ⁷Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁸Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁹Rheumatology Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland, ¹⁰Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ¹¹University of Otago, Christchurch, New Zealand, ¹²University of Auckland, Auckland, New Zealand
Background/Purpose: The ABCG2 Q141K (rs2231142) variant is an established cause of hyperuricaemia in Europeans. Although the effect size of ABCG2 rs2231142 on serum urate levels…
Abstract Number: 2277 • 2016 ACR/ARHP Annual Meeting
Exon Sequencing Reveals a Significant Burden of Non-Synonymous Variants in Both SLC22A11 (OAT4) and SLC22A12 (URAT1) in European Hyperuricemic Individuals
Tanya Flynn¹, James Boocock¹, Murray Cadzow¹, Ruth Topless¹, Amanda Phipps-Green¹, Nicola Dalbeth², Lisa K. Stamp³, David B. Mount⁴, Asim Mandal⁴, Hyon K. Choi⁵, Eli A. Stahl⁶ and Tony R. Merriman⁷, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ⁶Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, ⁷Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Common variants within the uric acid transporter genes SLC22A11 (OAT4) and SLC22A12 (URAT1) have been associated with hyperuricaemia and gout in multiple populations, but…
Abstract Number: 2282 • 2016 ACR/ARHP Annual Meeting
Ferritin Levels Are Associated with Urate and Gout – a Role for Iron Metabolism in Gout ?
Tahzeeb Fatima¹, Tony R. Merriman², Lisa K. Stamp³, Nicola Dalbeth⁴, Cory Iverson⁵ and Jeffrey N. Miner⁶, ¹University of Otago, Dunedin, New Zealand, ²Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶Discovery Biology, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Transferrin and its cell-surface receptor regulate iron uptake and ferritin sequesters free iron and acts as a store for excess iron. Ferritin has been…
Abstract Number: 3073 • 2016 ACR/ARHP Annual Meeting
Non-Additive Interaction of the Glucokinase Regulatory Protein and APOBEC1 Complementation Factor Loci with Alcohol Consumption to Influence the Risk of Gout
Humaira Rasheed¹, Lisa K. Stamp², Nicola Dalbeth³ and Tony R. Merriman⁴, ¹University of Engineering and Technology, Lahore, Pakistan, ²University of Otago, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Genome-wide association studies (GWAS) have identified loci associated with serum urate levels and the risk of gout. Some of these loci interact in a…
Abstract Number: 3188 • 2016 ACR/ARHP Annual Meeting
Association of Gout with Risk of Advanced Chronic Kidney Disease
Austin Stack¹, Betina Blak², Michelle Johnson³, Victoria Parsons³, Andrew Maguire⁴, Alyssa B Klein⁵, John Ferguson⁶ and Robert Morlock⁷, ¹Nephrology, University Hospital Limerick & Health Research Institute,University of Limerick, Limerick, Ireland, ²AstraZeneca,, Luton, United Kingdom, ³Oxon Epidemiology Ltd, London, United Kingdom, ⁴Epidemiology, Oxon Epidemiology Ltd, London, United Kingdom, ⁵AstraZeneca, Gaithersburg, MD, ⁶Graduate Entry Medical School, University of Limerick, Limerick, Ireland, ⁷Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: It is speculated that gout is a risk factor for kidney disease progression. The aim of this study was to evaluate the association of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.